Page 5 - Bladder Cancer Session
P. 5

Non-muscle Invasive Disease





          Non-muscle-invasive Bladder Cancer Pembrolizumab for the treatment of patients with high-risk (HR) non-

         muscle-invasive bladder cancer (NMIBC) unresponsive to BCG: Extended follow-up of KEYNOTE-057 cohort A



















































                                                                                                                                                                      Lancet Oncol 2021; 22: 919–30
                                                                                                                                                              BalarAV et al. SeoHK. UAA Congress 2020
   1   2   3   4   5   6   7   8   9   10